Molecular neurobiology

Parkinson’s-Related LRRK2 Protein Disrupts Brain Support Cells’ Removal of Alpha-Synuclein

Updated

Abstract

Astrocytes with the G2019S mutation in the LRRK2 gene show a decreased capacity to internalize and degrade fibrillary .

  • Mutations in the LRRK2 gene are common in familial Parkinson's disease and are associated with sporadic cases.
  • Impaired degradation of alpha-synuclein in neurons has been linked to pathogenic LRRK2 mutations.
  • Astrocytes, which are important brain cells, play a significant role in the pathology related to alpha-synuclein.
  • Astrocytes carrying the G2019S LRRK2 mutation were compared to wild-type astrocytes in their ability to handle fibrillary alpha-synuclein.
  • The study found that LRRK2 G2019S astrocytes have a reduced ability to clear alpha-synuclein through the endo-lysosomal pathway.
  • The reduction in alpha-synuclein clearance in these astrocytes is associated with a loss of function of .

Simplified

Key numbers

1.5 to 2×
Decrease in Internalization Capacity
Increase in α-syn deposits in G2019S astrocytes compared to wild-type.
94 ± 2%
Astrocyte Composition
Percentage of astrocytes identified in cultures from wild-type mice.

Full Text

What this is

  • This research investigates the role of LRRK2 mutations in astrocyte-mediated clearance of (α-syn) in Parkinson's disease (PD).
  • The study specifically examines the G2019S mutation, a common pathogenic variant linked to familial PD.
  • Findings indicate that astrocytes with the G2019S mutation have a reduced capacity to internalize and degrade α-syn, impacting their role in PD pathology.

Essence

  • Astrocytes with the G2019S LRRK2 mutation show impaired internalization and degradation of α-syn, suggesting a mechanism for PD progression. This impairment is linked to reduced function.

Key takeaways

  • Astrocytes carrying the G2019S mutation exhibit a decreased ability to internalize and degrade fibrillary α-syn. This suggests that LRRK2 mutations may hinder the astrocytic clearance of toxic proteins, contributing to PD pathology.
  • The study identifies as a key factor in α-syn clearance, with its reduced function in G2019S astrocytes correlating with impaired internalization of α-syn aggregates. This highlights a potential target for therapeutic intervention.

Caveats

  • The study focuses on in vitro models, which may not fully replicate the complex environment of the human brain. Further research is needed to validate findings in vivo.
  • The impact of other LRRK2 mutations beyond G2019S on astrocytic function remains unexplored, limiting the generalizability of the findings.

Definitions

  • alpha-synuclein (α-syn): A protein that aggregates in the brains of PD patients, contributing to neurodegeneration.
  • annexin A2 (AnxA2): A protein involved in intracellular trafficking and phagocytosis, crucial for the clearance of aggregated proteins.

Simplified

Funding

Competing interests

The authors declare that they have no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free